Few days ago, Relmada Therapeutics Inc (OTCMKTS:RLMD) jumped sharply from its base of $2.50 on massive volume to make a 52-week high of $4. Since then RLMD stock has been declining steadily moving close to level from where it started its run. The company was a target of hard mailer promotion promoted by Gramercy Strategic Partners LLC. The compensation for the promotion was $964,391 and the mailer appeared as a newspaper mockup.

The news

Along with the promotion emails, Relmada has been making some big announcements including the latest news of submission of Clinical Trial Application in Canada. It filed the application for its unique Oral Formulations of Buprenorphine. The ongoing projects of the company are compelling and indicate big things to come in the future. Relmada is a late-stage specialty Pharma firm working on innovative forms of proven drug offerings together with other chemical entities that potentially consider the areas of unmet medical need in alleviation of pain.

The portfolio

Relmada Therapeutics Inc (OTCMKTS:RLMD) possess a diversified portfolio of promising drug candidates. It includes four key products which are at various phases of development. It includes lead candidate drug d-Methadone, a treatment for neuropathic pain. The other drug candidates are MepiGel which is an orphan drug designated topical formulation of mepivacaine. The third one is BuTab which is oral dosage version of buprenorphine. Last product is LevoCap ER which is sustained release dosage version of the levorphanol.

The scope

Relmada’s product development measures are supported by the internationally acknowledged scientific expertise of research team. The company wants to mitigate clinical development costs and risks while potentially offering valuable products in key areas of unmet medical needs. Relmada is planning a first stage study to assess the tolerability and safety of BuTab in healthy subjects. It is meant for the cure of both chronic pain and opioid dependence.

Previous articlePositiveID Corp (OTCMKTS:PSID) Declines After A Paid Pump
Next articleUbiquity Inc (OTCBB:UBIQ) Acquires Coversant, Inc.
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.